Cravath and Saraf and Partners represented Viatris in the transaction while Shardul Amarchand Mangaldas & Co and Goodwin Procter advised Biocon Biologics. Viatris Inc. reached a…
- Homepage
- North America
- North America Legal Chronicle
- Viatris’ $3.335 Billion Combination of Biosimilars Portfolio with Biocon Biologics
Viatris’ $3.335 Billion Combination of Biosimilars Portfolio with Biocon Biologics
Tagged: 02-03-2022 Aanchal Khandelwal Aaron Gruber Aastha Trehan Abhishek Chansoria Aditya Sood Ajay Bhadu Akshay Jain Akshayy Nanda Alex Apostolopoulos Ankita Tiwari Anushka Bajpai Ayushi Harsh Benjamin Joseloff Bikash Jhawar Biocon Biologics Limited Brendon Rivard Cameron Buttermore Cecily Xi Christopher Davis Christopher Gonnella Cravath Swaine & Moore Cusaj Thomas Daniel Barabander David Crampton David Kappos Devika Menon Goodwin Procter Graham Defries Heath Ingram Huiya Wu Iqbal Khan J. Leonard Teti II Jennifer Merrigan Fay Jonathan J. Katz Joyce Law Justin Pierce Kara Kuritz Kelly Nichole King Kenny Walker-Durrant Keshav Pareek Kevin Walsh Kiran Sheffrin Lokesh Shah Lucy Sharples Margaret Segall D’Amico Mark Greene Matt Wetzel Matthew Morreale megadeals Michael Patrone Mohit Saraf Morgan Mordecai Murtaza Zoomkawala Navomi Koshy Nicole Peles Paayas Pandit Praniti Ganjoo Richard Matheny Robert Crawford Robert Stein Robert Ward Ryan Patrone Sahil Arora Samuel Beavers Sara Lepis Saraf and Partners Sarah Bock Satadru Goswami Shardul Amarchand & Mangaldas & Co. Shivani Suhag Susan Lee Tim Worden Viatris Vivek Pareek Wei Xu Yogendar Singh
Author: Laura Testa
…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here